Advertisement

International Deals

My time has been spent in ?Europe.? In the last two days, I have been to Italy four times, London and France each twice and made brief stops in Germany and Switzerland. The series of meetings that I have had with European companies has caused me to come to the conclusion that companies in that region are undervalued, undermanaged, underappreciated and unhappy with the lack of availabe capital. The companies are therefore looking to gain additional investor support from US venture capitalists. At

By | January 12, 2006

My time has been spent in ?Europe.? In the last two days, I have been to Italy four times, London and France each twice and made brief stops in Germany and Switzerland. The series of meetings that I have had with European companies has caused me to come to the conclusion that companies in that region are undervalued, undermanaged, underappreciated and unhappy with the lack of availabe capital. The companies are therefore looking to gain additional investor support from US venture capitalists. At the same time, European venture capitalists are expressing concern with the inability to find local IPO exits for many of their companies and are looking to the US to find better investees. Anonymous Quote of the Day: ?A good biotech CEO is like a bullfighter: he possesses agility, grace, courage to stare danger in the face and only the remote prospect of being paid well if he survives.?
Advertisement

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Advertisement
Life Technologies